In the field of rare and chronic specialty diseases, "no available treatment and long development timelines" has long been a difficult reality for many families. In 2026, Japan made a number of advances in the clinical translation of rare and difficult-to-treat diseases, drawing on its relatively efficient approval process and research capabilities.
A Chronic Kidney Disease Common in Asia: New Drug for IgA Nephropathy Nears Approval Submission
IgA nephropathy has a relatively high incidence among Asian populations, and effective treatments addressing both symptoms and underlying cause have long been lacking, with some patients eventually progressing to kidney failure and requiring dialysis. In 2026, phase III clinical trials for a new drug targeting this disease were completed in Japan, and the company involved plans to submit an approval application to the Ministry of Health, Labour and Welfare within the year. The new drug targets the underlying disease mechanism itself, with the potential to reduce the risk of declining kidney function and delay patients' progression toward dialysis or kidney transplantation.
Glycogen Storage Disease Type Ia: Gene Therapy Enters the Approval Review Stage
Glycogen storage disease type Ia (GSD Ia) is a rare inherited metabolic disorder; due to a congenital enzyme deficiency, patients face ongoing risk of hypoglycemia and progressive organ damage, and require a precisely controlled special feeding regimen to survive. In 2026, Japan formally accepted an approval application for a gene therapy product for this disease. The therapy uses advanced gene-modification technology, aiming to correct the patient's underlying genetic defect through a single injection, with the potential to offer a true cure. Globally, relatively few countries currently have the regulatory capacity and framework to review gene therapy products, and Japan is among the earlier movers in advancing this type of review.
Why Japan Is Positioned to Adopt These Innovative Therapies Early
This comes down to two structural and institutional factors in Japan: first, the PMDA's dedicated fast-track approval pathway for regenerative medicine and gene therapy, which allows products demonstrating clear efficacy to reach market early while still ensuring safety; and second, Japan's relatively complete clinical databases for diseases common in Asia, such as IgA nephropathy, along with collaboration between university hospitals and national research institutions that helps new drug development better reflect the physiological characteristics of Asian patients.
What This Means for International Patients
Advanced therapies including the new IgA nephropathy drug and the gene therapy product described above are expected to become legally available in Japan relatively early; Japanese hospitals also have relatively mature screening and early diagnosis technology in the fields of metabolic disease, genetic disease, and pediatric rare disease. At the same time, Japan maintains fairly strict end-to-end regulatory oversight of gene and regenerative medicine, aiming to ensure the safety and transparency of cross-border treatment. MIZUHO PHARMA can help arrange a remote consultation and medical record assessment with Japan's national-level rare disease and kidney disease specialists, along with full support including appointment booking and medical record translation.